VIENNA—At the St Gallen Breast Cancer Conference BCL-2 was named as a therapeutic target for patients with hormone-receptor positive breast cancer by Geoffrey J Lindeman BSc(Med) PhD, from the University of Melbourne and the Walter and Eliza Hall Institute of Medical Research and head of the Familial Cancer Centre at The Royal Melbourne Hospital, Australia. He discussed the clinical potential of BCL-2 modulation with Oncology Times reporter Sarah Maxwell.
You may also like...
Dog walking cuts breast cancer recurrence risk 29 Mar, 2013 Lack of EGFR Mutation Test Results Before Starting First Line Therapy for Advanced Lung Cancer Worsens Outcomes 27 Apr, 2015 Combined Intracavitary/Interstitial Brachytherapy: New benchmark for Cervical Cancer 5 May, 2015 Audio Journal of Oncology Volume 16 Number 10 25 May, 2008
- Previous story Tumor Microenvironment: Tumor Infiltrating Lymphocyte Score Predicts Breast Cancer Outcome
- Next story Targeting Bone Microenvironment in Breast Cancer
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014